TET1 and neoplasm: To test this hypothesis, we prepared a new EpC nanocarrier that simultaneously delivers 5-aza-dC, a DNMT inhibitor, and TET1 gene-encoding pDNA to cancer cells and investigated its anti-tumor effects on HCT116 colon cancer cells.